This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Get full access to this article
View all access options for this article.
References
1.
BenediniS, TerruzziI, LazzarinA, LuziL.Recombiant human growth hormone. Rationale for use in the treatment of HIV-associated lipodystrophy. Biodrugs.2008;22(2):101–112.
2.
LoJ, YouSM, CanavanB, Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: A randomized controlled trial. JAMA. 2008;300(5):509–519.
3.
GrunfeldC, ThompsonM, BrownSJ, ; Study 24380 Investigators Group. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr.2007;45(3):286–297.
4.
KotlerDP, MuurahainenN, GrunfeldC, et al. Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum. J Acquir Immune Defic Syndr. 2006;43(3):378–380. Erratum in: J Acquir Immune Defic Syndr. 2004;35(3):239–252.
5.
EngelsonES, GlesbyMJ, MendezD, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr. 2002;30:379–391.
6.
WankeC, GerriorJ, KantarosJ, CoakleyE, AlbrechtM.Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. 1999;13:2099–2103.
7.
MacallanDC, BaldwinC, MandaliaS, Treatment of altered body composition in HIV-associated lipodystrophy: Comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials. 2008;9(4):254–268.
8.
GlesbyMJ, AlbuJ, ChiuYL, Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: A randomized, double-blind, placebo-controlled, factorial trial. PLoS One. 2013;8(4):e61160.
9.
SivakumarT, MechanicO, FehmieDA, PaulB.Growth hormone axis treatments for HIV-associated lipodystrophy: A systematic review of placebo-controlled trials. HIV Med. 2011;12(8):453–462.
